Furthermore, Ohkuri T et al. found that STING-deficient mice had fewer IFN-γ-producing CD8+ T cells but increased infiltration of immune-suppressing cells, such as CD11b+Gr-1+ immature myeloid suppressor cells and CD25+Foxp3+ regulatory T (Treg) cells, in the tumor microenvironment [37], whereas STING agonist CDN treatment promoted cross-presentation and helped T cells recognize tumor cells [106]. Here, STING1 is linked to neoplasm.